Nuclear receptors and their endogenous ligands are involved in key biological functions, including development, homeostasis and metabolism, and functional molecules that can modulate receptor activities are of interest for basic research to elucidate the signaling pathways, as well as having potential therapeutic applications. Here, we summarize our recent work on the development of nuclear receptor ligands, focusing on thyroid hormone receptor (TR) antagonists, fluorescent ligands for progesterone receptors (PR), and inhibitors of histone methyltransferase (HMT). We have developed a series of potent TR antagonists bearing a thiazolidinedione group as a bioisoster of a polar amino acid group. Utilizing our library of fluorescent coumarin derivatives, we obtained a PR antagonist that exhibits fluorescence enhancement upon binding to PR. We also developed a series of HMT inhibitors based on the structure of adenosylmethionine (AdoMet), a cofactor in the methylation reaction, by introducing various alkylamino groups onto the nitrogen atom in place of the sulfur atom of AdoMet. Our compounds should be useful in functional analysis of these nuclear receptors and investigations of their signaling pathways.
Introduction
Nuclear receptors are ligand-inducible transcriptional factors that play important roles in many physiological functions, including development, homeostasis and metabolism. [1] [2] [3] The concentration and distribution of their endogenous ligands, such as estrogen, androgen, vitamin D 3 and retinoic acids, are strictly controlled, and disruption of the regulatory functions is associated with various physiological disorders. Thus, elucidation of the signaling pathways of these receptors is important for basic cell biology, and also has potential value for medicinal chemistry and clinical diagnosis.
Nuclear receptor ligands regulate gene transcription by binding to nuclear receptors, which generally form homo-or heterodimers with other nuclear receptors. Those receptors also interact with various transcriptional coregulatory proteins to form coactivator or corepressor complexes, resulting in the control of transcription of specific genes. 4, 5) Posttranslational modification of nuclear receptors and related proteins is also important, for example, histone-modifying enzymes regulate gene transcription [6] [7] [8] (Fig. 1 ). In addition to those genomic functions, various nongenomic functions are mediated through membrane-associated nuclear receptor proteins or other receptor proteins. [9] [10] [11] [12] For example, estradiol, the endogenous ligand of estrogen receptor (ER), also binds to cell-membrane or caveola-associated ER, as well as to other receptors such as GPER, one of the G-protein coupled receptors, inducing the generation of nitric oxide or activation of some kinases. [13] [14] [15] [16] Many functional molecules have been developed with the aim of studying or modulating the complex signaling pathways associated with nuclear receptors. Here, we describe our recent work on the development of thyroid hormone receptor (TR) antagonists, 17) as well as fluorescent ligands for progesterone receptors (PR), 18) and histone methyl transferase (HMT) inhibitors.
19) The compounds that we have developed are expected to be useful in functional analysis of these nuclear receptors and their signaling pathways. Finally, we briefly discuss future prospects for research in this area.
Thyroid Receptor Ligands with Thiazolidinedione Group as Bioisoster of Polar Aminoacid Group
heart rate. 20, 21) There are two major subtypes, TRα and TRβ. 22) TRα is widely expressed, but shows especially high expression in heart and skeletal muscles; its activation is associated with alteration of heart rate and rhythm. 23) There are two isoforms of TRβ, of which TRβ1 is also widely expressed, with high levels in the liver and brain, while TRβ2 expression is limited to the brain. Most actions of thyroid hormone in the liver, such as modulation of lipid metabolism, are regulated through the activation of TRβ1. 24, 25) Abnormal elevation of circulating throid hormones results in hyperthyroidism, which manifests clinically as weight-loss, hypermetabolism, reduced serum low-density lipoprotein (LDL) levels, cardiac arrhythmias, heart failure, muscle weakness, bone loss in postmenopausal women, and anxiety.
26)
Present clinical treatment of hyperthyroidism involves direct reduction of thyroid hormone production by inhibiting the synthesizing enzymes, or by ablating the thyroid gland surgically or with radioiodine, but because of the long half-life of thyroid hormones, these therapies take several weeks to restore a normal state. 27) In contrast, the direct suppression of TR functions is expected to be rapid. Therefore, several TR ligands have been developed as candidates for therapy of TRmediated diseases.
Endogenous thyroid hormones consist of a biaryl ether skeleton substituted with an α-alanine moiety at the para position of one benzene ring (1 position), and a hydroxyl group at the para position of the other benzene ring (4′ position). T 3 and T 4 possess three (3, 5, 3′ positions) or four (3, 5, 3′, 5′ positions) iodines, respectively (Fig. 2) with the hydroxyl group is called the outer ring. Based on the structure of the endogenous thyroid hormones, many thyromimetics have been developed in attempts to generate more potent, subtype-selective or tissue-selective TR agonists and antagonists. 28) For example, GC-1 was reported as a TRβ-subtype selective agonist, in which the polar group at the 1 position is an oxyacetic acid moiety, while the metabolically susceptible iodine atoms at the 3, 5 and 3′ positions are replaced with methyl or isopropyl groups, and the bridging atom between the two aryl rings is changed to a methylene group. 29) Introduction of a bulky group at the 5′ position provided TR antagonists such as NH- 3 30) (Fig. 3 ). We also developed TR ligands based on T 3 . We introduced a thiazolidinedione group, which is a good bioisoster for carboxylic acid and has also been used in ligands of other nuclear hormone receptors, 31, 32) as the terminal polar group, and obtained compound 1 as a TR agonist. 33) We also developed TR antagonists 2 by introducing an additional alkyl group at the bridging nitrogen atom, in place of the oxygen of T 3 17) (Fig. 4) . In transient transactivation assay in COS-1 cells transfected with hTRα or hTRβ, compounds 2 substituted with relatively large groups, such as N-benzyl (2d) or N-cyclohexylmethyl (2g), showed strong antagonistic activity against both TR subtypes (Fig. 5 ). This new class of antithyroid compounds should provide candidate drugs for clinical application and tools for elucidation of the physiological functions of thyroid hormone receptors.
Fluorescent Progesterone Receptor Ligands Based on the Coumarinscaffold
Progesterone receptor (PR) and its endogenous ligand, progesterone, play significant roles in female reproduction, including regulation of growth and differentiation of the uterus and mammary gland, ovulation, and establishment and maintenance of pregnancy. 34, 35) PR agonists are used in contraceptives, for hormone therapy in combination with estrogens, and in the treatment of gynecologic disorders such as endometriosis and uterine fibroids. PR antagonists also have potential clinical applications. So, novel PR-selective ligands may have potential therapeutic utility in various gynecological diseases, including hormone-dependent breast and prostate cancers, 36, 37) nonmalignant chronic conditions such as fibroids, 38, 39) and endometriosis. 40, 41) Mifepristone (Fig. 6 ) was the first clinically available PR antagonist. 42) However, mifeprostone and related derivatives bearing a steroid skeleton exhibit side effects partially related to cross-reactivity with steroid hormone receptors, such as estrogen receptor (ER), androgen receptor (AR), and glucocorticoid receptor (GR). Compared with steroidal PR ligands, non-steroidal ligands might have reduced side effects due to lower cross-reactivity with other steroid hormone receptors. So far, nitrogen-containing heterocycles fused with an arylsubstituted benzene ring, such as compounds 3 and 4, have been widely studied. [43] [44] [45] [46] [47] Considering the structures of these non-steroidal PR ligands, we thought that bicyclic 6-arylcoumarin would be an alternative scaffold. Coumarin is one of widely used fluorophore, and the fluorescence properties of its derivatives are known to depend upon the nature and position of substituents. Its derivatives have been utilized as laser dyes, 48) the emission layer in organic light-emitting diodes, 49) and fluorescent sensors.
50,51) Recently, we have constructed a coumarin derivative library by means of Suzuki-Miyaura coupling reaction between bromo and boronic acid moieties, and/or Huisgen 1,3-cycloaddition reaction between azide group and acetylene group (Fig. 7) . From this library, we have developed several fluorescent sensors, including a nitric oxide sensor and multi analyte-type sensor candidate, in which the modes of fluorescence change induced by two analytes are different from each other, that is, one is induces a change of fluorescence intensity, while the other induces a shift of emission maximum wavelength. [52] [53] [54] Due to these properties, coumarin-based PR ligand was thought to be a fluorescent ligand, which would be useful for studying the mechanisms of PR action, as well as in screening systems for the discovery and development of novel ligand molecules.
Therefore, we examined the PR activity of the compounds in our coumarin library, and found that compound 5 exhibited PR antagonistic activity. To optimize this lead compound, we synthesized a series of 6-arylcoumarins (Fig. 8) , and examined their biological activities by means of alkaline phosphatase Table 1 . The lead compound 5 exhibited PR antagonistic activity with an IC 50 value of 4.07 µm. Compounds without the 3-substituent, such as 6a, showed more potent PR antagonistic activity than 5 by one order of magnitude. The substituent effects on the 6-phenyl ring of 6-aryl-7-diethylaminocoumarins were not large, although in anilide-type PR antagonists such as 3, they were critical, that is, compounds with a cyano or nitro group on the phenyl ring showed potent activity. Regarding the effect of a 7-substituent on the coumarin structure, compounds 7 bearing a 7-dimethylamino group showed a slight increase in antagonistic activity, compared with the corresponding compound having a 7-diethylamino group. Replacement of the amino moiety with a 7-methoxyl (8) or 7-hydroxyl (9) group decreased the activity. Interestingly, the compound without any 7-substituent (10) showed similar antagonistic activity, and other compounds, such as 10b with a 4-cyanophenyl group or 10e with a 4-fluorophenyl group, had better IC 50 values.
18)
The effects of introduction of a heterocyclic ring on the coumarin are also examined. The introduction of 5-membered heterocycles was effective, as seen in compounds 11a and 11b with a 6-thiophen-2-yl group; those compounds showed potent PR antagonistic activity with IC 50 values of 0.22 and 0.54 µm, respectively. Introduction of a chloro group on the thiophene ring increased the activity, and compound 11c was 4.5 times more active than compound 11b. Introduction of a furan ring decreased the activity, compared to the 6-phenyl derivative, while introduction of the cyano-substituted pyrrole ring increased the potency. Compound 11e was the most potent PR antagonist (IC 50 : 65 nm) among our coumarin derivatives.
The binding affinity of selected compounds (6a, 11a, 11b, 11c, 11e) toward some nuclear receptors (hPR, hER, hAR, hGR, hMR) was also examined by competitive binding assay using recombinant ligand binding domain of each human nuclear receptor. Compounds 6a and 11a bearing a 7-diethylamino group showed potent PR binding affinity, while compounds 11b, 11c, and 11e showed weaker binding affinity. Although the reason for the difference between the binding experiments and AP assay results of these compounds is unclear, the lipophilic or hydrophobic character of the 7-substituent may have different effects under the different assay conditions. None of the coumarin derivatives examined bound to ER and MR, and only compounds 6a and 11a bound to AR and GR, with weak and moderate affinities, respectively. The fluorescence properties of 6a in the presence of PR are shown in Fig. 9 . Compound 6a exhibited weak fluorescence in the absence of PR ligand binding domain (LBD) in buffer, while the addition of PR LBD substantially increased the fluorescence of 6a, that is, 500 nm PR-LBD induced about an 8-fold fluorescent enhancement. The increased fluorescence of 6a in the presence of PR LBD was blocked by the addition of progesterone. Similar experiments with ER did not result in any increase of the fluorescence of 6a. These results indicate that compound 6a shows a specific fluorescence enhancement upon binding with the PR-LBD, and thus 6a is a candidate fluorescent sensor for PR.
Bisubstrate-Type Inhibitors of Histone Methyltransferase, SET7/9
Histone proteins undergo multiple types of post-translational modifications, which serve to activate or inactivate expression of various genes. [55] [56] [57] Histone methylation is one of these post-translational modifications, and is regulated by enzymes such as histone lysine methyltransferase (HMT), protein arginine methyltransferase (PRMT) and histone demethylase (HDM). 58, 59) While the acetylation of lysine residues of histone induces gene activation, the influence of methylation depends on the methylation site; for example, methylation of lysine 4 of histone H3 (H3K4) results in activation, whereas methylation of H3K9 results in suppression. Some of the enzymes involved are reported to function as coregulators of nuclear receptors. For example, coactivator-associated arginine methyltranferase 1 (CARM1), which methylates H3R17/H3R26, was reported to be a nuclear receptor activator.
60) Demethylase LSD1 could function as an androgen receptor coactivator.
61) Interestingly, the substrates of these histone-modifying enzymes were not limited to histone proteins. One of the HMTs, SET7/9, can methylate p53, which functions as a tumor suppressor and transcriptional modulator, as well as nuclear receptor estrogen receptor α (ER α). [62] [63] [64] To elucidate the physiological functions of these enzymes, selective inhibitors are required. In the case of HMTs, chaetocin was identified as a selective inhibitor of SUV39 from a library of natural compounds.
65) BIX-01294, a G9a inhibitor, was developed based on screening of a large chemical library 66) (Fig. 10) . Subsequently, several inhibitors have also been reported. [67] [68] [69] [70] [71] In addition, derivatives of cofactors related to the methylation reaction have been reported as methyltransferase inhibitors. In the methylation reaction, the methyl group of the cofactor adenosylmethionine (AdoMet) is transferred to nitrogen of the substrate lysine residue, yielding methylated lysine and adenosylhomocysteine (AdoHcy), as shown in Fig.  11 . AzaAdoMet, an analogue of AdoMet in which the bridging sulfur atom is replaced with nitrogen, and sinefungin are reported to inhibit AdoMet-dependent methyltransferases, such as DNA methyltransferase.
72,73)
Recently, we also reported derivatives of these cofactors as novel bisubstrate-type inhibitors of histone methyltransferase, SET7/9.
19) The crystal structure of the ternary complex of human SET7/9 with histone substrate peptide and cofactor AdoHcy has been elucidated. 74) In this structure, the peptide substrate and cofactor bind on opposite surfaces of the enzyme. The target lysine residue (Lys4) of the substrate peptide is inserted into a narrow channel passing through the enzyme, affording access to the cofactor (Fig. 12a) . Cofactors or their analogues conjugated with a substructure of the substrate could be utilized as bisubstrate inhibitors, which are able to interact with both substrate-binding sites, in this case the cofactor-binding site and the substrate peptidebinding site, to provide high potency and selectivity. 75) For example, ATP derivatives conjugated with substrate peptide have been reported as bisubstrate kinase inhibitors, 76) and a conjugate of substrate estradiol with adenosine, which is a substructure of cofactor NADPH, has been reported as an inhibitor of 17β-hydroxysteroid dehydrogenase. 77, 78) So, based on the structure of the ternary complex, we designed novel derivatives (12a-d) of AzaAdoMet, in which the nitrogen that replaces the sulfur atom of AdoMet is coupled to various alkylamino groups via an ethylene linker, as inhibitor candidates (Fig. 12b) . The introduced nitrogen is expected to form a hydrogen-bonding network similar to that of the lysine residue of substrate peptide, involving Tyr245 and a water molecule tightly bound to Tyr305. Further, the alkyl group (R) is expected to interact with hydrophobic side chains of amino acids that form the channel through the enzyme, such as Leu267, Tyr305, Tyr335 and Tyr337. In order to study the effect of the nitrogen atom, a derivative without such nitrogen, 12e, was also designed (Fig. 12b) .
The inhibitory activity of the synthesized compounds towards histone methyltransferase SET7/9 was examined by utilizing anti-monomethyl-histone H3 (Lys4) antibody, and the results are shown in Fig. 13 . Compounds 12a-d showed relatively strong inhibitory activity compared with 12e, which lacks the additional nitrogen. The inhibitory activities were little affected by the nature of the alkyl group attached to the nitrogen, though compound 12c with a n-hexyl group was slightly more potent than the other compounds. These compounds are expected to be lead compounds for development of more potent and selective inhibitors.
Conclusion and Future Perspective
We have developed several functional molecules that can directly regulate the functions of nuclear receptors TR and PR, as well as some compounds incorporating a fluorescent pharmacophore that may be available as fluorescent sensors. We have also developed a series of inhibitors for histone methyltransferase. As already mentioned, the signaling pathways associated with nuclear receptors are complex, and functional molecules such as those described here are essential as tools for uncovering these pathways, in addition to having possible therapeutic potential. Additionally, spatial and temporal control of the actions of such ligands would be an enormous advantage for detailed study of signaling pathways. For example, caged nuclear receptor ligands, [79] [80] [81] whose activity can be controlled (uncaged) by light irradiation at a specified location and time, would be also effective. Control of the localization of ligands by conjugation with large protein or polymer structures is another approach that has been used to study membrane-associated nuclear receptor function.
82,83)
Increased selectivity of ligands is also an important goal. For example, estradiol could also bind membrane associated estrogen receptor and seven-transmembrane G-protein-coupled receptor, GPR30, and selective ligands against this GPR30 have also been reported. [84] [85] [86] Continued research in these areas is expected to contribute not only to academic research, but also to human health.
